824 related articles for article (PubMed ID: 23913253)
1. Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists.
Makar RS; Zhukov OS; Sahud MA; Kuter DJ
Am J Hematol; 2013 Dec; 88(12):1041-4. PubMed ID: 23913253
[TBL] [Abstract][Full Text] [Related]
2. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
[TBL] [Abstract][Full Text] [Related]
3. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center.
González KJ; Zuluaga SO; DaRos CV; Rodríguez PP; Martí AC
Ann Hematol; 2017 Mar; 96(3):507-508. PubMed ID: 27975127
[No Abstract] [Full Text] [Related]
4. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia.
Al-Samkari H; Kuter DJ
Am J Hematol; 2018 Dec; 93(12):1501-1508. PubMed ID: 30187942
[TBL] [Abstract][Full Text] [Related]
5. Thrombopoietin-receptor agonists in haematological disorders: the Danish experience.
Gudbrandsdottir S; Frederiksen H; Hasselbalch H
Platelets; 2012; 23(6):423-9. PubMed ID: 22185370
[TBL] [Abstract][Full Text] [Related]
6. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
[TBL] [Abstract][Full Text] [Related]
7. [Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study].
Weber E; Moulis G; Mahévas M; Guy C; Lioger B; Durieu I; Hunault M; Ramanantsoa M; Royer B; Default A; Pérault-Pochat MC; Moachon L; Bernard N; Bardy G; Jonville-Bera AP; Geniaux H; Godeau B; Cathébras P
Rev Med Interne; 2017 Mar; 38(3):167-175. PubMed ID: 27793553
[TBL] [Abstract][Full Text] [Related]
8. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study.
Mahévas M; Fain O; Ebbo M; Roudot-Thoraval F; Limal N; Khellaf M; Schleinitz N; Bierling P; Languille L; Godeau B; Michel M
Br J Haematol; 2014 Jun; 165(6):865-9. PubMed ID: 24725224
[TBL] [Abstract][Full Text] [Related]
9. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
[TBL] [Abstract][Full Text] [Related]
10. Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia.
Mitchell WB; Pinheiro MP; Boulad N; Kaplan D; Edison MN; Psaila B; Karpoff M; White MJ; Josefsson EC; Kile BT; Bussel JB
Am J Hematol; 2014 Dec; 89(12):E228-34. PubMed ID: 25132654
[TBL] [Abstract][Full Text] [Related]
11. Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration.
Arumugaswamy A; He S; Quach H; Brotchie J; Grigg A
Intern Med J; 2014 May; 44(5):519-21. PubMed ID: 24816314
[No Abstract] [Full Text] [Related]
12. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres.
Lakhwani S; Perera M; Fernández-Fuertes F; Ríos de Paz MA; Torres M; Raya JM; Hernández MT
Eur J Haematol; 2017 Oct; 99(4):372-377. PubMed ID: 28759125
[TBL] [Abstract][Full Text] [Related]
13. Thrombopoietin receptor agonists in patients with persistent or chronic immune thrombocytopenia.
Agnelli Giacchello J; Valeri F; Boccadoro M; Borchiellini A
Eur J Haematol; 2018 Mar; 100(3):304-307. PubMed ID: 29243329
[TBL] [Abstract][Full Text] [Related]
14. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P
Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624
[TBL] [Abstract][Full Text] [Related]
15. Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study.
Neunert C; Despotovic J; Haley K; Lambert MP; Nottage K; Shimano K; Bennett C; Klaassen R; Stine K; Thompson A; Pastore Y; Brown T; Forbes PW; Grace RF;
Pediatr Blood Cancer; 2016 Aug; 63(8):1407-13. PubMed ID: 27135461
[TBL] [Abstract][Full Text] [Related]
16. Moving towards a new era in the management of chronic immune thrombocytopenia.
Wadenvik H; Olsson B
Ann Hematol; 2010 Jul; 89 Suppl 1():87-93. PubMed ID: 20339846
[TBL] [Abstract][Full Text] [Related]
17. Thrombopoietin receptor agonists in hereditary thrombocytopenias.
Rodeghiero F; Pecci A; Balduini CL
J Thromb Haemost; 2018 Sep; 16(9):1700-1710. PubMed ID: 29956472
[TBL] [Abstract][Full Text] [Related]
18. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
[TBL] [Abstract][Full Text] [Related]
19. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
Atkinson K
Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797
[TBL] [Abstract][Full Text] [Related]
20. Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia.
Lozano ML; Mingot-Castellano ME; Perera MM; Jarque I; Campos-Alvarez RM; González-López TJ; Carreño-Tarragona G; Bermejo N; Lopez-Fernandez MF; de Andrés A; Valcarcel D; Casado-Montero LF; Alvarez-Roman MT; Orts MI; Novelli S; Revilla N; González-Porras JR; Bolaños E; Rodríguez-López MA; Orna-Montero E; Vicente V
Sci Rep; 2019 Nov; 9(1):16680. PubMed ID: 31723222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
